Business Context and Reporting Period
Company: Capricor Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 7, 2017
Event: Entry into a Material Definitive Agreement (Amendment No. 2 to the CIRM Notice of Loan Award).
Key Financial Metrics
This filing does not contain standard financial statements (revenue, profit, cash flow, or margins). The only specific financial figure disclosed is the revised loan award amount.
- Revised CIRM Loan Award Total: $14,405,857
Material Changes
Capricor, Inc., a wholly owned subsidiary of the Company, entered into Amendment No. 2 to the CIRM Notice of Loan Award on June 7, 2017. This amendment was executed due to a previously announced reduction in the number of patients to be enrolled in the ALLSTAR Phase II Trial. Key changes include:
- Reduction in Award Amount: The total award amount was reduced to $14,405,857.
- Removal of Milestones: Operational Milestones Nos. 3 and 4 have been removed.
- Reporting Adjustments: Certain reporting requirements were removed to align with the elimination of specific enrollment milestones.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on future outlook, or a discussion of general risks. The primary contingency noted is the scaling back of the ALLSTAR Phase II Trial enrollment, which directly necessitated the reduction in the CIRM loan award and the removal of associated operational milestones.
Investor Verification Checklist
- Verify the full text of Exhibit 10.1 (Amendment No. 2 to the CIRM Notice of Loan Award) for complete legal terms.
- Confirm the specific impact of the reduced patient enrollment on the ALLSTAR Phase II Trial timeline and future funding requirements.
- Review prior filings to determine the original loan award amount and the specific details of the removed Operational Milestones Nos. 3 and 4.